Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Rheumatol. doi: /nrrheum

Published byHilary Flynn Modified over 5 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Rheumatol. doi: /nrrheum"— Presentation transcript:

1 Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.83
Figure 2 Estimated serious infection rates among clinical trials of biologics in rheumatoid arthritis Figure 2 | Estimated serious infection rates among clinical trials of biologics in rheumatoid arthritis. The incidence rate of serious infection (number of unique patients with events per 100 patient-years exposure) across clinical trials (including randomized control trials and long-term extension trials) investigating biologics for the treatment of rheumatoid arthritis are displayed using clinical trial data published between 1999 and All trials included patients with moderate to severely active rheumatoid arthritis. JAK, Janus kinase. This figure was adapted with permission obtained from Strand, V. et al. Arthritis Res. Ther. 17, 362 (2015)51, which is published under an open-access licence ( by BioMed Central Ltd. This figure was adapted with permission obtained from Strand, V. et al. Arthritis Res. Ther. 17, 362 (2015)51, which is published under an open-access licence ( by BioMed Central Ltd. Rose-John, S. et al. (2017) The role of IL‑6 in host defence against infections: immunobiology and clinical implications Nat. Rev. Rheumatol. doi: /nrrheum

Download ppt "Nat. Rev. Rheumatol. doi: /nrrheum"

Similar presentations

Figure 2 Electromechanical properties of OIHPs

Figure 2 Electromechanical properties of OIHPs
Figure 6 Selected examples of TERS applications in material systems

Figure 6 Selected examples of TERS applications in material systems
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Historical evolution of the clinical classification and

Figure 1 Historical evolution of the clinical classification and
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Figure 1 Grip strength across the lifecourse

Figure 1 Grip strength across the lifecourse
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Enthesitis versus synovitis

Figure 1 Enthesitis versus synovitis
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 2 Risk factors for sarcopenia

Figure 2 Risk factors for sarcopenia
Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors
Figure 4 Simplified T cell and antigen presenting

Figure 4 Simplified T cell and antigen presenting
Figure 8 Implanted devices for the management of heart failure

Figure 8 Implanted devices for the management of heart failure
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 5 Defects in the JAK–STAT signalling pathway

Figure 5 Defects in the JAK–STAT signalling pathway
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 3 Simplified EULAR and GRAPPA

Figure 3 Simplified EULAR and GRAPPA

Similar presentations

Ads by Google